Yüklüyor......
Predictors of availability of long-acting medication for opioid use disorder
BACKGROUND: The U.S. Food and Drug Administration has approved three long-acting medications for opioid use disorder (MOUD): extended-release naltrexone (XR-NTX) in 2010, a subdermal buprenorphine implant in 2016, and a depot buprenorphine injection in 2017. Long-acting MOUD options may improve adhe...
Kaydedildi:
| Yayımlandı: | Drug Alcohol Depend |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6910228/ https://ncbi.nlm.nih.gov/pubmed/31593871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugalcdep.2019.107586 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|